Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**adapalene + benzoyl peroxide + doxycycline** is a combination drug regimen used for the treatment of severe acne vulgaris. It consists of adapalene, a third-generation topical retinoid with comedolytic and anti-inflammatory properties; benzoyl peroxide, a topical antimicrobial agent; and doxycycline, an oral tetracycline-class antibiotic that inhibits bacterial protein synthesis and decreases inflammation. This combination targets multiple pathogenic factors in acne, including abnormal keratinization, Propionibacterium acnes colonization, and inflammation. Clinical studies have shown the combination is more effective than either agent alone in reducing total, inflammatory, and non-inflammatory acne lesions, and is considered a cost-effective and safer alternative to oral isotretinoin in certain severe cases[1][3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on adapalene + benzoyl peroxide + doxycycline.